

Italfarmaco S.p.A. study no: DSC/13/2984/05

Page 1 of 1

Table 14.2.3.3 Summary of Normalization of IGF-1 (nmol/ml) at the End of the Treatment Period  
(Intent-to-treat Analysis Set)

Period		Treatment			
		100 mcg Octreotide (N=41) n (%)	500 mcg ITF2984 (N=43) n (%)	1000 mcg ITF2984 (N=47) n (%)	2000 mcg ITF2984 (N=42) n (%)
1	Yes	3 ( 7.3)	2 ( 4.7)	2 ( 4.3)	7 ( 16.7)
	No	8 ( 19.5)	10 ( 23.3)	7 ( 14.9)	5 ( 11.9)
2	Yes	6 ( 14.6)	0	5 ( 10.6)	6 ( 14.3)
	No	6 ( 14.6)	8 ( 18.6)	7 ( 14.9)	5 ( 11.9)
3	Yes	3 ( 7.3)	1 ( 2.3)	2 ( 4.3)	4 ( 9.5)
	No	8 ( 19.5)	10 ( 23.3)	9 ( 19.1)	4 ( 9.5)
4	Yes	2 ( 4.9)	2 ( 4.7)	2 ( 4.3)	4 ( 9.5)
	No	5 ( 12.2)	9 ( 20.9)	9 ( 19.1)	7 ( 16.7)
Overall	Yes	14 ( 34.1)	5 ( 11.6)	11 ( 23.4)	21 ( 50.0)
	No	27 ( 65.9)	37 ( 86.0)	32 ( 68.1)	21 ( 50.0)

N = the number of subjects in the analysis set receiving the specified treatment.

n = the number of subjects with a measurement.

(%) = n/N\*100.

Source: Listing 16.2.6.1

PROGRAM NAME:T\_NORMIGF\_01.SAS

DATE OF RUN:12SEP2016

TIME OF RUN: 11:52:59

DATE OF EXTRACTION:25MAY2016